FDA perspective on “Where are we? Where can we go?” 12 th Annual FDA & the Changing Paradigm for Blood Regulation 16 January 2009 -- Las Vegas, NV. Gilliam B. Conley Director, Division of Inspections & Surveillance FDA, Center for Biologics Evaluation & Research
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
FDA perspective on “Where are we?Where can we go?”12th Annual FDA & the Changing Paradigm for Blood Regulation16 January 2009 -- Las Vegas, NV
Gilliam B. Conley
Director, Division of Inspections & Surveillance
FDA, Center for Biologics Evaluation & Research
Office of Compliance & Biologics Quality
We will discuss
Note: These numbers represent a snapshot in time from our inspections database. Because of the further routine review following an investigator’s initial recommendation for an OAI inspection decision, the year-end actual numbers are fewer than the 14 reported here.
Find on the web:
WL - http://www.fda.gov/foi/warning.htm
ADL - http://www.fda.gov/ora/frequent/default.htm
Please join in the Q & A session
at the conclusion
of this morning’s session.